Search
forLearn
5 / 801 resultslearn threonine
learn Synergen Complex ®
learn APISCALP™
learn C 13-15 alkane
Research
5 / 1000+ results
research Theoretical investigation of the conformational space of baicalin
The study found that baicalin has different stable shapes in gas and water, with two shapes better for interacting with positive charges in water.
research Crystal Structure of 17-.BETA.-Benzoyloxy-16-.BETA.-methylpregna-4,6-diene-3,20-dione.
A new antiandrogen compound was made and its detailed three-dimensional shape was described.
research Crystal Structure of Minoxidil
Minoxidil's crystal structure shows two different molecule shapes and nitrogen states.
research Crystal Structure of 3-Oxo-4-Aza-5-Alpha-Androstone-17 β-Tert-Butyl Carboxamide with an O···H–(C, N) Acceptor Four-Center Hydrogen Bond
The research shows that hydrogen bonds greatly affect the crystal structure of a Finasteride derivative.
research Volume imaging to interrogate cancer cell-tumor microenvironment interactions in space and time
Advanced imaging methods have improved understanding of cancer cell interactions and treatment strategies.
Community Join
5 / 1000+ resultscommunity The Real Cause Of Androgenetic Alopecia
Androgenetic alopecia is caused by DHT affecting hair growth. Finasteride and minoxidil are used to manage hair loss by blocking DHT and promoting hair growth.
community Finasteride, dutasteride, and oral min- My experience
User took Fin for 3 years, Dut for 7 months, and oral Min for 2 months without side effects. Fin stopped hair loss for 2 years, Dut maintained hair, and oral Min regrew thinning hair.
community Can't believe I've slept on microneedling for so long.
Microneedling with minoxidil and finasteride greatly improves hair regrowth. Using 0.5mm depth every other day boosts minoxidil absorption without side effects.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community Cosmo Pharmaceutical (Breezula) fiscal results. Top Line Six month results expected early in the second half of this year.
Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.